Perfuze has developed multiple neurovascular catheters receiving 510(k) and CE Mark approval for its zipline access catheter, and is in an active IDE study for its super-bore aspiration catheter. Perfuze closed its Series A investment round of €22.5M in 2022 bringing total capital raised to ~€35M and is being clinically tested in a 180-patient, 20-site, U.S. pivotal trial in pursuit of FDA approval for the thrombectomy catheter. Perfuze is hiring its Lead CRA/Clinical Trial Manager.
We have partnered with Wayne Allen, CEO, and Veronica Lewis, Director of Clinical Affairs, to hire our Lead CRA/Clinical Trial Manager. This position will be responsible for clinical site startup and management for our IDE study while supporting cases in the Core Labs to answer technical details about the study protocol. This position will support site initiation visits while managing our CRO across 12-15 clinical sites for our 100+ patient study in the U.S.
Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland and is a medical device company developing next-generation “super-bore” catheter technology to treat ischemic stroke. The founders have over 30 years combined MedTech experience within start-up and large corporations and are committed to bringing devices to market that have the potential to transform the treatment of acute ischemic stroke.
We develop devices intended to increase the rate of the First Pass Effect underpinned by:
Co-founder & CEO
Director Clinical Affairs
Co-founder & CTO
Lifeblood™ supports global MedTech Startups with Talent Acquisition and Fundraising Strategies. We build full-scale startup teams from Board and C-level executives to entry-level individual contributors and from early-stage R&D through multi-national commercialization phases.Approaching two decades of experience in the MedTech industry, our talent acquisition services and team-building efforts are the results of 2,000+ successful hires for 500+ companies in 6 continents. We have facilitated more than $220 million for MedTech startups with our fundraising strategies and global investor network.
People and money are the lifeblood capital of startups. Learn from our entrepreneurs and investors as we demystify raising and investing capital on our MedTech Money Podcast Series.